JP2016537366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537366A5 JP2016537366A5 JP2016531020A JP2016531020A JP2016537366A5 JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5 JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently selected
- heterocyclyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1(C)C2=C(C(N)=O)C(*)=**2C(*)(*)C(*)(*)*1C(**)=O Chemical compound CC1(C)C2=C(C(N)=O)C(*)=**2C(*)(*)C(*)(*)*1C(**)=O 0.000 description 21
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904116P | 2013-11-14 | 2013-11-14 | |
| US61/904,116 | 2013-11-14 | ||
| PCT/US2014/065599 WO2015073767A1 (en) | 2013-11-14 | 2014-11-14 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537366A JP2016537366A (ja) | 2016-12-01 |
| JP2016537366A5 true JP2016537366A5 (https=) | 2017-12-21 |
| JP6494622B2 JP6494622B2 (ja) | 2019-04-03 |
Family
ID=51952052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531646A Expired - Fee Related JP6494624B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
| JP2016531020A Expired - Fee Related JP6494622B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531646A Expired - Fee Related JP6494624B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9273058B2 (https=) |
| EP (2) | EP3068784B1 (https=) |
| JP (2) | JP6494624B2 (https=) |
| CN (2) | CN105916856B (https=) |
| AR (1) | AR098414A1 (https=) |
| ES (2) | ES2718218T3 (https=) |
| TW (1) | TW201605859A (https=) |
| UY (1) | UY35834A (https=) |
| WO (2) | WO2015073763A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| JP6513075B2 (ja) * | 2014-02-27 | 2019-05-15 | 国立大学法人 東京大学 | オートタキシン阻害活性を有する縮合ピラゾール誘導体 |
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
| EP3458455B1 (en) * | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| EP3481835A4 (en) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF |
| EP3484886B1 (en) * | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| BR112019006110A2 (pt) | 2016-09-28 | 2019-09-10 | Blade Therapeutics Inc | moduladores de calpaína e usos terapêuticos dos mesmos |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| CA3070004A1 (en) | 2017-07-27 | 2019-01-31 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11292791B2 (en) | 2017-09-15 | 2022-04-05 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) * | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN111484442B (zh) * | 2018-06-01 | 2021-11-09 | 杭州阿诺生物医药科技有限公司 | 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法 |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CA3126334A1 (en) | 2019-01-11 | 2020-07-16 | Shionogi & Co., Ltd. | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity |
| AU2020210998A1 (en) * | 2019-01-25 | 2021-09-16 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of 1,2,3-triazolo(1,5-a)pyrazines derivative and preparation method for crystal form |
| CN111484497B (zh) * | 2019-01-25 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 |
| CN111484498B (zh) * | 2019-01-25 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法 |
| CA3128946A1 (en) | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2022023341A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof |
| CN114057745A (zh) * | 2020-07-29 | 2022-02-18 | 江苏恒瑞医药股份有限公司 | 一种三氮唑并[1,5-a]吡嗪制备方法及其应用 |
| JP2023541465A (ja) * | 2020-09-17 | 2023-10-02 | ヤンセン ファーマシューティカ エヌ．ベー． | カゼインキナーゼ１デルタモジュレーター |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| WO2022166778A1 (zh) * | 2021-02-04 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 一种衣壳蛋白抑制剂的药物组合物及其制备方法 |
| EP4469457A4 (en) * | 2022-01-27 | 2026-01-21 | Broad Inst Inc | CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS |
| AU2023296166A1 (en) * | 2022-06-13 | 2024-11-28 | Shionogi & Co., Ltd. | Crystal of dihydropyridinone derivative or solvate thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160915A0 (en) * | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
| DE602004020685D1 (de) * | 2003-12-11 | 2009-05-28 | Aventis Pharma Inc | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon |
| US20050222171A1 (en) * | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| CN102223798A (zh) | 2008-09-24 | 2011-10-19 | 巴斯夫欧洲公司 | 用于防治无脊椎动物害虫的吡唑化合物 |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
-
2014
- 2014-11-13 AR ARP140104277A patent/AR098414A1/es unknown
- 2014-11-13 TW TW103139448A patent/TW201605859A/zh unknown
- 2014-11-13 UY UY0001035834A patent/UY35834A/es unknown
- 2014-11-14 JP JP2016531646A patent/JP6494624B2/ja not_active Expired - Fee Related
- 2014-11-14 EP EP14802796.4A patent/EP3068784B1/en not_active Not-in-force
- 2014-11-14 CN CN201480073199.9A patent/CN105916856B/zh not_active Expired - Fee Related
- 2014-11-14 ES ES14802796T patent/ES2718218T3/es active Active
- 2014-11-14 US US14/541,343 patent/US9273058B2/en active Active
- 2014-11-14 EP EP14806145.0A patent/EP3068785B1/en not_active Not-in-force
- 2014-11-14 JP JP2016531020A patent/JP6494622B2/ja not_active Expired - Fee Related
- 2014-11-14 WO PCT/US2014/065594 patent/WO2015073763A1/en not_active Ceased
- 2014-11-14 CN CN201480073088.8A patent/CN105916855B/zh not_active Expired - Fee Related
- 2014-11-14 US US15/034,217 patent/US9598423B2/en active Active
- 2014-11-14 ES ES14806145T patent/ES2744636T3/es active Active
- 2014-11-14 WO PCT/US2014/065599 patent/WO2015073767A1/en not_active Ceased
-
2016
- 2016-01-13 US US14/994,346 patent/US20160122358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537366A5 (https=) | ||
| JP2016537369A5 (https=) | ||
| JP6474068B2 (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP2016507502A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2018522879A5 (https=) | ||
| PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| JP2015520140A5 (https=) | ||
| JP2017518344A5 (https=) | ||
| JP2018522866A5 (https=) | ||
| JP2018516238A5 (https=) | ||
| JP2017511360A5 (https=) | ||
| JP2013532652A5 (https=) | ||
| JP2016515560A5 (https=) | ||
| JP2016508135A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2013512903A5 (https=) | ||
| JP2018522867A5 (https=) | ||
| JP2014513139A5 (https=) | ||
| RU2016134751A (ru) | Соединения | |
| RU2010143455A (ru) | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов | |
| JP2014506582A5 (https=) | ||
| JP2016531868A5 (https=) | ||
| JP2017531678A5 (https=) |